Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 9 (September)

1. Delivering regional thrombolysis via a hub-and-spoke model.
   J R Soc Med, 103(9): 363-9. [Abstract] [Full-text]
2. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
   J Nucl Med, 51(9): 1337-43. [Abstract] [Full-text]
3. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers.
   FASEB J, 24(9): 3122-34. [Abstract] [Full-text]
4. Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.
   FASEB J, 24(9): 3160-70. [Abstract] [Full-text]
5. Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis.
   J Vasc Surg, 52(3): 658-62; discussion 662-3. [Abstract] [Full-text]
6. Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting beta-agonist inhaler therapy in asthma.
   J Allergy Clin Immunol, 126(3): 505-10. [Abstract] [Full-text]
7. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
   Lancet Oncol, 11(9): 853-60. [Abstract] [Full-text]
8. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
   Lancet Oncol, 11(9): 845-52. [Abstract] [Full-text]
9. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
   Ophthalmology, 117(9): 1792-9. [Abstract] [Full-text]
10. Agitation thrombolysis for fresh iatrogenic IVC thrombosis in patients with Budd-Chiari syndrome.
    J Vasc Surg, 52(3): 782-4. [Abstract] [Full-text]
11. Defining the pathway to insulin-like growth factor system targeting in cancer.
    Biochem Pharmacol, 80(8): 1115-24. [Abstract] [Full-text]
12. Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum Ca2+-ATPase with thapsigargin and thapsigargin analogs.
    J Biol Chem, 285(37): 28883-92. [Abstract] [Full-text]
13. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
    Cancer Lett, 297(1): 91-100. [Abstract] [Full-text]
14. In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer.
    Cancer Lett, 297(1): 56-64. [Abstract] [Full-text]
15. RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells.
    Cancer Lett, 297(1): 65-74. [Abstract] [Full-text]
16. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
    Cancer Lett, 297(1): 91-100. [Abstract] [Full-text]
17. In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer.
    Cancer Lett, 297(1): 56-64. [Abstract] [Full-text]
18. RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells.
    Cancer Lett, 297(1): 65-74. [Abstract] [Full-text]
19. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    N Engl J Med, 363(7): 640-52. [Abstract] [Full-text]
20. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    JAMA, 304(10): 1073-81. [Abstract] [Full-text]
21. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus.
    J Clin Endocrinol Metab, 95(9): 4206-16. [Abstract] [Full-text]
22. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
    Br J Cancer, 103(6): 796-801. [Abstract] [Full-text]
23. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
    Br J Cancer, 103(6): 845-51. [Abstract] [Full-text]
24. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
    Br J Cancer, 103(6): 759-64. [Abstract] [Full-text]
25. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery.
    N Engl J Med, 363(11): 1038-49. [Abstract] [Full-text]
26. Compartmental targeting for mTHPC-based photodynamic treatment in vivo: Correlation of efficiency, pharmacokinetics, and regional distribution of apoptosis.
    Int J Radiat Oncol Biol Phys, 78(2): 563-71. [Abstract] [Full-text]
27. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Gynecol Oncol, 119(1): 26-31. [Abstract] [Full-text]
28. Overcoming TRAIL resistance in ovarian carcinoma.
    Gynecol Oncol, 119(1): 157-63. [Abstract] [Full-text]
29. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
    Gynecol Oncol, 119(1): 48-52. [Abstract] [Full-text]
30. Targeted trials in ovarian cancer.
    Gynecol Oncol, 119(1): 151-6. [Abstract] [Full-text]
31. Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer.
    Gynecol Oncol, 119(1): 87-91. [Abstract] [Full-text]
32. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era.
    Am J Respir Crit Care Med, 182(6): 790-6. [Abstract] [Full-text]
33. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Int J Radiat Oncol Biol Phys, 78(2): 513-20. [Abstract] [Full-text]
34. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
    Int J Radiat Oncol Biol Phys, 78(2): 472-8. [Abstract] [Full-text]
35. Quality-of-life-adjusted survival analysis of concurrent chemo radiotherapy for locally advanced (nonmetastatic) nasopharyngeal cancer.
    Int J Radiat Oncol Biol Phys, 78(2): 454-60. [Abstract] [Full-text]
36. Antiretroviral therapy as HIV prevention: status and prospects.
    Am J Public Health, 100(10): 1867-76. [Abstract] [Full-text]
37. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial.
    Am J Public Health, 100(10): 1896-903. [Abstract] [Full-text]
38. Electrochemotherapy treatment of a recalcitrant earlobe keloid scar with chronic lymphocytic leukaemia infiltration.
    J Plast Reconstr Aesthet Surg, 63(10): e733-6. [Abstract] [Full-text]
39. Forearm pyomyositis in a breast cancer patient on chemotherapy.
    J Plast Reconstr Aesthet Surg, 63(10): e737-9. [Abstract] [Full-text]
40. Variation among pediatric urologists and across 2 continents in antibiotic prophylaxis and evaluation for prenatally detected hydronephrosis: a survey of American and European pediatric urologists.
    J Urol, 184(4): 1710-5. [Abstract] [Full-text]
41. Same setting laparoscopic antegrade continence enema and antegrade bladder neck injection for constipation and urinary incontinence in the spina bifida population.
    J Urol, 184(4): 1644-50. [Abstract] [Full-text]
42. Outcome after discontinuing prophylactic antibiotics in children with persistent vesicoureteral reflux.
    J Urol, 184(4): 1594-7. [Abstract] [Full-text]
43. Toxicity of PAMAM dendrimers to Chlamydomonas reinhardtii.
    Aquat Toxicol, 100(2): 187-93. [Abstract] [Full-text]
44. Anterior chamber and vitreous concordance in endophthalmitis: implications for prophylaxis.
    Arch Ophthalmol, 128(9): 1136-9. [Abstract] [Full-text]
45. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
    Arch Ophthalmol, 128(9): 1100-3. [Abstract] [Full-text]
46. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy?
    Ann N Y Acad Sci, 1205(1): 268-76. [Abstract] [Full-text]
47. Estrogen therapy and Alzheimer's dementia.
    Ann N Y Acad Sci, 1205(1): 245-53. [Abstract] [Full-text]
48. Exploring pharmacists' perceptions of the feasibility and value of pharmacist prescribing of antimicrobials in secondary care in Scotland.
    Int J Pharm Pract, 18(5): 312-9. [Abstract] [Full-text]
49. Testing a trigger tool as a method of detecting harm from medication errors in a UK hospital: a pilot study.
    Int J Pharm Pract, 18(5): 305-11. [Abstract] [Full-text]
50. A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
    Cancer Invest, 28(8): 833-8. [Abstract] [Full-text]
51. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study.
    Cancer Invest, 28(8): 820-7. [Abstract] [Full-text]
52. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
    J Infect Dis, 202(8): 1254-64. [Abstract] [Full-text]
53. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review.
    J Am Acad Dermatol, 63(4): 689-702. [Abstract] [Full-text]
54. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    J Clin Oncol, 28(27): 4247-54. [Abstract] [Full-text]
55. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
    J Clin Oncol, 28(27): 4162-9. [Abstract] [Full-text]
56. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    J Clin Oncol, 28(27): 4240-6. [Abstract] [Full-text]
57. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    J Clin Oncol, 28(27): 4170-6. [Abstract] [Full-text]
58. Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.
    J Clin Oncol, 28(27): 4228-32. [Abstract] [Full-text]
59. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    J Clin Oncol, 28(27): 4199-206. [Abstract] [Full-text]
60. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
    J Clin Oncol, 28(27): 4142-8. [Abstract] [Full-text]
61. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    J Clin Oncol, 28(27): 4184-90. [Abstract] [Full-text]
62. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
    J Clin Oncol, 28(27): 4177-83. [Abstract] [Full-text]
63. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.
    Mol Pharmacol, 78(4): 560-8. [Abstract] [Full-text]
64. Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling.
    Mol Pharmacol, 78(4): 550-7. [Abstract] [Full-text]
65. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
    Mol Pharmacol, 78(4): 577-87. [Abstract] [Full-text]
66. Chain-dependent photocytotoxicity of tricationic porphyrin conjugates and related mechanisms of cell death in proliferating human skin keratinocytes.
    Biochem Pharmacol, 80(9): 1373-85. [Abstract] [Full-text]
67. Chain-dependent photocytotoxicity of tricationic porphyrin conjugates and related mechanisms of cell death in proliferating human skin keratinocytes.
    Biochem Pharmacol, 80(9): 1373-85. [Abstract] [Full-text]
68. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
    Ann Intern Med, 153(6): 358-67. [Abstract] [Full-text]
69. Usefulness of intravenously administered fluid replenishment for detection of patent foramen ovale by transesophageal echocardiography.
    Am J Cardiol, 106(7): 1054-8. [Abstract] [Full-text]
70. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    J Natl Cancer Inst, 102(18): 1432-46. [Abstract] [Full-text]
71. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
    J Natl Cancer Inst, 102(18): 1413-21. [Abstract] [Full-text]
72. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.
    J Acquir Immune Defic Syndr, 55(2): 217-20. [Abstract] [Full-text]
73. Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation?
    Dig Dis Sci, 55(10): 2999-3004. [Abstract] [Full-text]
74. Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments.
    Proc Natl Acad Sci U S A, 107(38): 16530-5. [Abstract] [Full-text]
75. Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis.
    Endocrinology, 151(10): 4643-53. [Abstract] [Full-text]
76. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Thorax, 65(10): 915-20. [Abstract] [Full-text]
77. An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin.
    Am J Ophthalmol, 150(4): 498-504.e1. [Abstract] [Full-text]
78. Use of glaucoma medications: state of the science and directions for observational research.
    Am J Ophthalmol, 150(4): 569-574.e9. [Abstract] [Full-text]
79. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
    Blood, 116(12): 2026-32. [Abstract] [Full-text]
80. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
    Blood, 116(12): 2040-5. [Abstract] [Full-text]
81. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
    Blood, 116(12): 2070-7. [Abstract] [Full-text]
82. Enzyme-nanoparticle conjugates for biomedical applications.
    Methods Mol Biol, 679: 165-82. [Abstract] [Full-text]
83. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
    Am J Hematol, 85(10): 818-9. [Abstract] [Full-text]
84. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
    Am J Hematol, 85(10): 812-5. [Abstract] [Full-text]
85. Goal-directed fluid management based on the pulse oximeter-derived pleth variability index reduces lactate levels and improves fluid management.
    Anesth Analg, 111(4): 910-4. [Abstract] [Full-text]
86. Pitfalls in chronobiology: a suggested analysis using intrathecal bupivacaine analgesia as an example.
    Anesth Analg, 111(4): 980-5. [Abstract] [Full-text]
87. Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination.
    J Surg Oncol, 102(5): 361-5. [Abstract] [Full-text]
88. Antimicrobial drug use in a small Indian community hospital.
    Trop Doct, 40(4): 194-8. [Abstract] [Full-text]
89. Injection-induced sciatic nerve injury in Ugandan children.
    Trop Doct, 40(4): 223-4. [Abstract] [Full-text]
90. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial.
    Cancer Radiother, 14(6): 530-4. [Abstract] [Full-text]
91. Dendrimer templated construction of silver nanoparticles.
    Adv Colloid Interface Sci, 160(1): 76-87. [Abstract] [Full-text]
92. Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials.
    Eur J Surg Oncol, 36(10): 997-1003. [Abstract] [Full-text]
93. Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer.
    Eur J Surg Oncol, 36(10): 963-8. [Abstract] [Full-text]
94. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
    Cancer, 116(19): 4613-21. [Abstract] [Full-text]
95. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
    Cancer, 116(19): 4580-9. [Abstract] [Full-text]
96. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
    Cancer, 116(19): 4597-604. [Abstract] [Full-text]
97. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Cancer, 116(19): 4573-9. [Abstract] [Full-text]
98. Antibiotics-impregnated ventricular catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF infections: a prospective randomised clinical trial.
    J Neurol Neurosurg Psychiatry, 81(10): 1064-7. [Abstract] [Full-text]
99. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
    Int J Radiat Oncol Biol Phys, 78(3): 696-702. [Abstract] [Full-text]
100. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
     Int J Radiat Oncol Biol Phys, 78(3): 821-7. [Abstract] [Full-text]
101. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
     Leuk Res, 34(11): 1453-8. [Abstract] [Full-text]
102. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
     Cancer Lett, 298(1): 74-87. [Abstract] [Full-text]
103. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment.
     Cancer Lett, 298(1): 34-49. [Abstract] [Full-text]
104. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
     Int J Radiat Oncol Biol Phys, 78(3): 696-702. [Abstract] [Full-text]
105. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
     Int J Radiat Oncol Biol Phys, 78(3): 821-7. [Abstract] [Full-text]
106. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
     Leuk Res, 34(11): 1453-8. [Abstract] [Full-text]
107. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
     Cancer Lett, 298(1): 74-87. [Abstract] [Full-text]
108. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment.
     Cancer Lett, 298(1): 34-49. [Abstract] [Full-text]
109. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
     Cancer Lett, 298(1): 74-87. [Abstract] [Full-text]
110. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment.
     Cancer Lett, 298(1): 34-49. [Abstract] [Full-text]
111. The economic case for new stroke thrombolytics.
     Stroke, 41(10): S59-62. [Abstract] [Full-text]
112. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.
     Stroke, 41(10): S54-8. [Abstract] [Full-text]
113. Ultrasound-assisted thrombolysis for stroke therapy: better thrombus break-up with bubbles.
     Stroke, 41(10): S50-3. [Abstract] [Full-text]
114. Thrombolysis with plasmin: implications for stroke treatment.
     Stroke, 41(10): S45-9. [Abstract] [Full-text]
115. Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled trial.
     Arch Intern Med, 170(17): 1578-83. [Abstract] [Full-text]
116. Antibiotic prophylaxis in the management of complex midface and frontal sinus trauma.
     Laryngoscope, 120(10): 1940-5. [Abstract] [Full-text]
117. Association between human immunodeficiency virus infection and stiffness of the common carotid artery.
     Stroke, 41(10): 2163-70. [Abstract] [Full-text]
118. Effect of weekend compared with weekday stroke admission on thrombolytic use, in-hospital mortality, discharge disposition, hospital charges, and length of stay in the Nationwide Inpatient Sample Database, 2002 to 2007.
     Stroke, 41(10): 2323-8. [Abstract] [Full-text]
119. Patterns and predictors of discharge statin prescription among hospitalized patients with intracerebral hemorrhage.
     Stroke, 41(10): 2271-7. [Abstract] [Full-text]
120. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
     Br J Cancer, 103(7): 993-1000. [Abstract] [Full-text]
121. Intra-articular microparticles for drug delivery to the TMJ.
     J Dent Res, 89(10): 1039-44. [Abstract] [Full-text]
122. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
     Prostate, 70(15): 1658-71. [Abstract] [Full-text]
123. Evaluation of clearance mechanisms with transscleral drug delivery.
     Invest Ophthalmol Vis Sci, 51(10): 5205-12. [Abstract] [Full-text]
124. Posterior linear stromal haze formation after simultaneous photorefractive keratectomy followed by corneal collagen cross-linking.
     Invest Ophthalmol Vis Sci, 51(10): 5030-3. [Abstract] [Full-text]
125. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
     Prostate, 70(15): 1658-71. [Abstract] [Full-text]
126. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
     Int J Cancer, 127(11): 2699-706. [Abstract] [Full-text]
127. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
     Int J Cancer, 127(11): 2699-706. [Abstract] [Full-text]
128. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
     Int J Cancer, 127(11): 2699-706. [Abstract] [Full-text]
129. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
     N Engl J Med, 363(14): 1313-23. [Abstract] [Full-text]
130. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
     J Clin Oncol, 28(28): 4307-15. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.